Publikace
- Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine2022 | Farmaceutická fakulta v Hradci Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- 2,6-Dihydroxybenzaldehyde analogues of the iron chelator salicylaldehyde isonicotinoyl hydrazone: Increased hydrolytic stability and cytoprotective activity against oxidative stress2018 | Farmaceutická fakulta v Hradci Králové
- Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite2017 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?2016 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products2016 | Farmaceutická fakulta v Hradci Králové
- Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury2016 | Farmaceutická fakulta v Hradci Králové
- Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo2015 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents2015 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites2015 | Farmaceutická fakulta v Hradci Králové
Loading network view...